RECEPTOR-MEDIATED CALCIUM ENTRY IN ACINAR CELLS
RECEPTOR-MEDIATED CALCIUM ENTRY IN ACINAR CELLS
批准号:
3083109
负责人:
TRISTRAM D BAHNSON
金额:
$7.48万
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-07-01 至 1997-06-30
中文摘要
腺泡细胞中受体介导的钙进入
英文摘要
Receptor Mediated Calcium Entry in Acinar Cells
Calcium (Ca2+) is the final messenger coupling cellular stimulation to
secretion in acinar cells. Cellular stimulation causes a rise in
intracellular Ca2+ concentration ([Ca2+]i) when Ca2+ is released from
intracellular stores via the action of soluble second messengers. This
release results in the depletion of intracellular Ca2+ stores. Receptor-
mediated calcium entry (RMCE) is a process whereby receptor activation
mediates calcium entry independently of membrane potential. RCME is
observed after agonist stimulation in secretory cells, and is necessary to
"refill" calcium stores and to restore cellular responsiveness. A portion
of RMCE in secretory cells has been shown to be dependent on the
"emptiness" of intracellular calcium stores and will be refereed to here as
depletion-activated calcium entry. The long-range goal of this project is
to describe the mechanism of depletion-activated calcium entry and the
intracellular messengers or mechanisms that are responsible for its
regulation. Details about the mechanism of depletion-activated calcium
entry, or its regulation, remain unknown. The candidate's preliminary
experiments have shown that: a) Depletion-activated calcium entry can be
measured in Ca2+ depleted acinar cells using the patch-clamp technique and
FURA-2 fluorescence, b) nitroprusside, which raises intracellular cyclic
quanosine-3,5-monophosphate, can potentiate calcium entry. The specific
aims of the research are: a) to define the regulation of depletion-
activated calcium entry by determining how cyclic nucleotides or other
messengers act to modulate calcium entry, and b) to determine whether
depletion-activated calcium entry is carried by a second messenger-operated
Ca2+ channel or by another mechanism such as an ion exchanger; these
experiments will use both patch-clamp recording a FURA-2 fluorescence
measurements. The suitability and feasibility of the methods have been
demonstrated in the preliminary studies. These preliminary studies provide
evidence that the proposed experiments will yield useful results.
GRANT-R01NS23077
Epilepsy is a major debilitating disorder of the central nervous system
which is characterized by abnormal electrical activity of the brain. This
disease affects the lives of millions of people. Although epilepsy can be
treated in many cases with drug therapy, a significant number of patients
are intractable to drug treatment. The aim of this research plan is to
determine the cellular mechanisms of epilepsy in humans, in order to assist
in developing improved treatments for seizure-disorders. The cellular
mechanisms of seizure activity will be investigated by studying the
electrical activity which occurs in the dentate gyrus of temporal lobe
epileptic patients. The dentate gyrus holds a crucial position in the
control of electrical events in the hippocampus, an important site of
seizure initiation. The electrical activity of neurons in the dentate
gyrus will be examined in brain slices from temporal lobe epileptic
patients. The relative influences of excitatory and inhibitory synaptic
input, and intrinsic membrane properties on hyperexcitability of the
dentate gyrus will be examined. The hypothesis of a longitudinal gradient
in hyperexcitability (seizure susceptibility) of the dentate gyrus will be
tested by performing physiological recordings at several locations along
the dentate gyrus. The interpretation of these physiological observations
will be assisted by histological assessment (synaptic reorganization and
cell loss) of tissue from the same regions. The results from the proposed
experiments will provide greatly needed information concerning the
physiological basis of seizure disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PH III: AZIMILIDE LONG TERM TREATMENT
-
批准号:6565319
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2001
-
负责人:TRISTRAM D BAHNSON
-
依托单位:
PH III: AZIMILIDE CONTROLLED TRIAL
-
批准号:6565318
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2001
-
负责人:TRISTRAM D BAHNSON
-
依托单位:
PH III: AZIMILIDE LONG TERM TREATMENT
-
批准号:6415260
-
项目类别:
-
资助金额:$29.31万
-
财政年份:2000
-
负责人:TRISTRAM D BAHNSON
-
依托单位:
PH III: AZIMILIDE LONG TERM TREATMENT
-
批准号:6503059
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2000
-
负责人:TRISTRAM D BAHNSON
-
依托单位:
PH III: AZIMILIDE CONTROLLED TRIAL
-
批准号:6415259
-
项目类别:
-
资助金额:$29.31万
-
财政年份:2000
-
负责人:TRISTRAM D BAHNSON
-
依托单位:
PH III: AZIMILIDE CONTROLLED TRIAL
-
批准号:6463021
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2000
-
负责人:TRISTRAM D BAHNSON
-
依托单位:
PH III: AZIMILIDE CONTROLLED TRIAL
-
批准号:6503058
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2000
-
负责人:TRISTRAM D BAHNSON
-
依托单位:
PH III: AZIMILIDE LONG TERM TREATMENT
-
批准号:6463022
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2000
-
负责人:TRISTRAM D BAHNSON
-
依托单位:
PH III: AZIMILIDE LONG TERM TREATMENT
-
批准号:6302923
-
项目类别:
-
资助金额:$4.09万
-
财政年份:1999
-
负责人:TRISTRAM D BAHNSON
-
依托单位:
PH III: AZIMILIDE CONTROLLED TRIAL
-
批准号:6263420
-
项目类别:
-
资助金额:$4.09万
-
财政年份:1998
-
负责人:TRISTRAM D BAHNSON
-
依托单位:
PH III: AZIMILIDE LONG TERM TREATMENT
-
批准号:6263421
-
项目类别:
-
资助金额:$4.09万
-
财政年份:1998
-
负责人:TRISTRAM D BAHNSON
-
依托单位:
RECEPTOR-MEDIATED CALCIUM ENTRY IN ACINAR CELLS
-
批准号:2210402
-
项目类别:
-
资助金额:$8.14万
-
财政年份:1992
-
负责人:TRISTRAM D BAHNSON
-
依托单位:
RECEPTOR-MEDIATED CALCIUM ENTRY IN ACINAR CELLS
-
批准号:3083110
-
项目类别:
-
资助金额:$7.44万
-
财政年份:1992
-
负责人:TRISTRAM D BAHNSON
-
依托单位:
RECEPTOR-MEDIATED CALCIUM ENTRY IN ACINAR CELLS
-
批准号:2210403
-
项目类别:
-
资助金额:$8.13万
-
财政年份:1992
-
负责人:TRISTRAM D BAHNSON
-
依托单位:
RECEPTOR-MEDIATED CALCIUM ENTRY IN ACINAR CELLS
-
批准号:2210404
-
项目类别:
-
资助金额:$8.31万
-
财政年份:1992
-
负责人:TRISTRAM D BAHNSON
-
依托单位:
PH III: AZIMILIDE CONTROLLED TRIAL
-
批准号:6302922
-
项目类别:
-
资助金额:$4.09万
-
财政年份:--
-
负责人:TRISTRAM D BAHNSON
-
依托单位:
海外基金